Jazz Pharmaceuticals plc (JAZZ) Reports $1.2 Billion Q4 Revenue, Beats $1.17B Estimate
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is among the 11 Best Pot Stocks to Buy According to Hedge Funds.
On February 25, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported Q4 revenue of $1.2 billion, exceeding consensus estimates of $1.17 billion and marking 10% year-over-year growth. According to Renee Gala, president and chief executive officer of Jazz Pharmaceuticals, 2025 was an exceptional year for the company. Management highlighted 2025 as its 21st consecutive year of top-line growth, underscoring operational execution and portfolio durability. It boasted a revenue of $1.2 billion for the fourth quarter of 2025, reflecting 10% year-over-year growth and the company's highest revenue quarter to date.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) cited momentum heading into 2026, including the potential launch of zanidatamab in gastroesophageal adenocarcinoma, ongoing commercialization of Modeyso and Zepzelca, and continued strength from Epidiolex and Xywav in epilepsy and narcolepsy, respectively. Jazz projects FY2026 revenue of between $4.25 and $4.5 billion, compared to consensus expectations near $4.5 billion.
On January 29, TD Cowen raised its price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $220 from $205 and maintained a Buy rating ahead of Q4 results, reflecting updated modeling and pipeline visibility.
Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on oncology and neuroscience, with a differentiated rare disease portfolio. It is considered a "stealth" cannabis company due to its ownership of the cannabidiol (CBD) drug Epidiolex.
While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Top Crypto Investor: XRP Developers Know Something Big Is Coming
The App That Ends Crypto Profit/Loss Math: Everything is Automatic
Hyperliquid Surges 10% as $1.16 Billion Buybacks Fuel HYPE Flippening Speculation
Egypt eyes first aerial survey in 40 years to map mineral riches
